GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (BSP:N1VO34) » Definitions » Cyclically Adjusted FCF per Share

Novo Nordisk AS (BSP:N1VO34) Cyclically Adjusted FCF per Share : R$1.14 (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Novo Nordisk AS Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Novo Nordisk AS's adjusted free cash flow per share for the three months ended in Mar. 2025 was R$0.235. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is R$1.14 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Novo Nordisk AS's average Cyclically Adjusted FCF Growth Rate was 12.40% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 16.40% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 15.30% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 14.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Novo Nordisk AS was 21.60% per year. The lowest was 8.40% per year. And the median was 16.25% per year.

As of today (2025-05-31), Novo Nordisk AS's current stock price is R$50.90. Novo Nordisk AS's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was R$1.14. Novo Nordisk AS's Cyclically Adjusted Price-to-FCF of today is 44.65.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Novo Nordisk AS was 104.10. The lowest was 27.84. And the median was 42.84.


Novo Nordisk AS Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Novo Nordisk AS's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk AS Cyclically Adjusted FCF per Share Chart

Novo Nordisk AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.62 0.71 0.79 0.85 1.15

Novo Nordisk AS Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.88 1.03 1.12 1.15 1.14

Competitive Comparison of Novo Nordisk AS's Cyclically Adjusted FCF per Share

For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk AS's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Novo Nordisk AS's Cyclically Adjusted Price-to-FCF falls into.


;
;

Novo Nordisk AS Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novo Nordisk AS's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.235/120.2000*120.2000
=0.235

Current CPI (Mar. 2025) = 120.2000.

Novo Nordisk AS Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 0.123 100.300 0.147
201509 0.154 100.200 0.185
201512 0.096 99.800 0.116
201603 0.086 100.200 0.103
201606 0.162 100.600 0.194
201609 0.152 100.200 0.182
201612 0.099 100.300 0.119
201703 0.117 101.200 0.139
201706 0.107 101.200 0.127
201709 0.139 101.800 0.164
201712 0.037 101.300 0.044
201803 0.095 101.700 0.112
201806 0.201 102.300 0.236
201809 0.145 102.400 0.170
201812 0.053 102.100 0.062
201903 0.104 102.900 0.121
201906 0.187 102.900 0.218
201909 0.228 102.900 0.266
201912 0.035 102.900 0.041
202003 0.159 103.300 0.185
202006 0.478 103.200 0.557
202009 0.261 103.500 0.303
202012 -0.288 103.400 -0.335
202103 0.237 104.300 0.273
202106 0.516 105.000 0.591
202109 0.450 105.800 0.511
202112 -0.125 106.600 -0.141
202203 0.440 109.900 0.481
202206 0.421 113.600 0.445
202209 0.385 116.400 0.398
202212 0.019 115.900 0.020
202303 0.519 117.300 0.532
202306 0.422 116.400 0.436
202309 0.597 117.400 0.611
202312 -0.138 116.700 -0.142
202403 0.108 118.400 0.110
202406 0.810 118.500 0.822
202409 0.724 118.900 0.732
202412 -0.102 118.900 -0.103
202503 0.235 120.200 0.235

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Novo Nordisk AS  (BSP:N1VO34) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Novo Nordisk AS's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=50.90/1.14
=44.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Novo Nordisk AS was 104.10. The lowest was 27.84. And the median was 42.84.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Novo Nordisk AS Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Novo Nordisk AS's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk AS Business Description

Industry
Address
Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk AS Headlines

No Headlines